{"organizations": [], "uuid": "4c2eb34106a1926858e5c95ac91aed242f4b3a58", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biogen-reports-top-line-results-fr/brief-biogen-reports-top-line-results-from-phase-2b-study-of-natalizumab-idUSASM000J1H", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen Reports Top-Line Results From Phase 2B Study Of Natalizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.889, "site_type": "news", "published": "2018-02-07T20:36:00.000+02:00", "replies_count": 0, "uuid": "4c2eb34106a1926858e5c95ac91aed242f4b3a58"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biogen-reports-top-line-results-fr/brief-biogen-reports-top-line-results-from-phase-2b-study-of-natalizumab-idUSASM000J1H", "ord_in_thread": 0, "title": "BRIEF-Biogen Reports Top-Line Results From Phase 2B Study Of Natalizumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Biogen Inc:\n* BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE\n* BIOGEN INC - PRIMARY AND SECONDARY EFFICACY ENDPOINTS WERE NOT MET IN ACTION 2 STUDY\n* BIOGEN INC - FURTHER DEVELOPMENT OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE WILL NOT BE PURSUED\n* BIOGEN INC - IN MIDDLE OF 2018, BIOGEN PLANS TO INITIATE A GLOBAL PHASE 3 STUDY OF BIIB093 IN INDIVIDUALS WITH LARGE HEMISPHERIC INFARCTION\n* BIOGEN INC - IN STUDY, SECONDARY AND EXPLORATORY ENDPOINTS SUGGESTED NATALIZUMAB TREATMENT IMPROVED CLINICAL OUTCOMES COMPARED WITH PLACEBO Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T20:36:00.000+02:00", "crawled": "2018-02-09T05:48:05.016+02:00", "highlightTitle": ""}